SIGA Technologies siga.com


Public lists: Pharma Startups (6570)

SIGA designs and develops novel countermeasures to prevent and treat serious infectious diseases, with an emphasis on biological warfare defense. SIGAs leading program is ST-246®, an oral therapeutic agent active against orthopoxviruses including smallpox. Additional programs target arenaviruses such as Lassa fever, filoviruses such as Ebola and Marburg, flaviviruses such as Dengue fever, and other category A diseases. The company has developed a proprietary discovery platform that can be...Show all

SIGA designs and develops novel countermeasures to prevent and treat serious infectious diseases, with an emphasis on biological warfare defense. SIGAs leading program is ST-246®, an oral therapeutic agent active against orthopoxviruses including...Show all

Company (IPO / Went public)

Phone: 212-672-9100

Fax:

420 Lexington Avenue

New York, 10170
New York, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
SIGA Technologies $32.6M Oct 12, 2006
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related SIGA Technologies Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Highbridge Capital ManagementNew York, New York, United StatesPIPE - III, PIPE - II
Downsview CapitalPrivate EquityDeerfield, Illinois, United StatesPIPE - III, PIPE - II
Iroquois Capital GroupMerchant BankNashville, Tennessee, United StatesPIPE - III, PIPE - II
Omicron CapitalDiversified Financial ServicesNew York, New York, United StatesPIPE - III, PIPE - II
Rockmore CapitalHedge FundNew York, New York, United StatesPIPE - III
See all 5 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Inhibitors and methods of inhibiting bacterial and viral pathogens Dec 22, 2016 May 15, 2018 Patent
St-246 liquid formulations and methods Dec 01, 2015 Mar 06, 2018 Patent
Amorphous tecovirimat preparation Apr 27, 2017 Feb 13, 2018 Patent
Methods of preparing tecovirimat Dec 08, 2016 Jan 09, 2018 Patent
Polymorphic forms of st-246 and methods of preparation Dec 04, 2015 Aug 29, 2017 Patent
See all 52 patents